Cullinan Therapeutics Announces Positive Initial Data From Pivotal Phase 2B Rezilient1 Study of Zipalertinib
Cullinan Therapeutics公佈了Zipalertinib的關鍵性2B期Rezilient1研究的積極初步數據
Cullinan Therapeutics Announces Positive Initial Data From Pivotal Phase 2B Rezilient1 Study of Zipalertinib
Cullinan Therapeutics公佈了Zipalertinib的關鍵性2B期Rezilient1研究的積極初步數據
譯文內容由第三人軟體翻譯。